Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
The economist article couple with the Air Liquide news gives us some of the best macro news we’ve seen in ages. We really do seem to have turned the corner in terms of the pace of technology adoption and thought- leadership. Take a look at the Air Liquide share chart over the last thirty years. Those guys just don’t make big mistakes.
I’m genuinely surprised / confused that ITM is still in the ‘20’s today.
I’m going to stay in this stock for years so don’t need to make short term predictions but I will make one - that a Santa rally will take this over 40p by mid Jan....i think ITM is irresistible to an institutional investor here and expect a new name to start building a position.
Fair. It’s been a long hard road for all of us....
Johntay, you seem to be overlooking the fact that the allergy market is a very large and very valuable one, serving a real need in many suffers, including those with life-threatening anaphylactic risk (AGY have a promising earlier stage peanut programme, by the way).
sure, the placebo affect is tricky here and in other therapeutic areas but that doesn't stop scientists from trying to design trials that prove efficacy and it doesn't stop investors from potentially making an excellent return. Perhaps I shouldn't have mentioned Circassia. There's a lot of differences between a cat allergy and a pollen trial, a lot of lessons recently learned and, and this is my key point, a LOT in the price down here already.
You say you're now 'out'. I'll take a decent-sized wager that you were never 'in'. identify your sell trade today and maybe I'll believe you!
I'm actually quite happy to pick more of this up - and just have at 14.2. This stock is practically on 1x £65mn-odd of sales. It's incredibly cheap vs global allergy peers and in a different league compared to the usual pre-revenue stuff on AIM...If you chuck in Brexit and the Birch trial delay then I think you have the recipe for a very miss-priced stock. Yes, the trial delay is a pain but it's better to have a delayed trial than one that's rushed/flawed. In any trial for allergy you're up against a placebo affect which needs to be carefully benchmarked. Look at what happened to Circassia when they tried in Cat. After the trial data release Circassia came up with factors like altitude, location, seasonality but it was too late, the damage had been done and the trial results filed.
The contract research guys carrying out this Birch trial for Allergy have clearly learned a lot from trial failures elsewhere and want to give the trial the best chance of success. Also, note that a carefully constructed trial protocol and analysis is EXACTLY what the FDA will want to see when it considers the next big money stage for Allergy - Phase 3 in the US.
you won't get any RNS news today or on monday, in my view. nowadays, this is effectively an american company and it's Thanksgiving. the yanks are giving themselves a rare long-weekend holiday.
have to say that the sustained buying today has surprised me. suggests that there's appetite for stock from a grown-up and not just the pump&dump brigade. good luck, all.
Not sure whether Synairgen will put out their own RNS ot no....I guess they should do,
Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non-Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF).
Arix led the A$24 million (£13.4 million) financing for Pharmaxis in August, acquiring an 11.1% equity stake. Arix’s Ed Rayner joined the Pharmaxis Board of Directors in September 2018.
The announcement can be accessed on Pharmaxis’ website at http://www.pharmaxis.com.au/investor-centre/news/ and full text of the announcement from Pharmaxis is contained below.
Pharmaxis will host an investor research briefing on Tuesday, 20 November from 10am to 12.00pm (AEDT). The event will provide an overview of the Pharmaxis drug discovery pipeline including the anti-inflammatory drug currently being developed by Boehringer Ingelheim, work in collaboration with the Garvan Institute of Medical Research on an anti-fibrotic LOX inhibitor targeting pancreatic cancer and the anti-fibrotic LOXL2 inhibitor program currently completing phase 1 trials and extended toxicity studies.
This is a unique opportunity to hear directly from the Pharmaxis executive research team along with the perspectives of a committed pharmaceutical partner and a leading medical research institute. A live webcast will be accessible to all investors via the homepage of the Pharmaxis website at www.pharmaxis.com.au and will be available for replay after the event.
Fred, thanks. but relevance of the article to Rene is...?
Think it’s mainly macro - investors looking for decent quality ftse250 laggards for a Q4 which normally looks after smaller caps and will do so in spades if we get a framework agreement on Brexit.
There has been a big seller in recent months which has hurt this chart. Encouragingly, a fair amount of stock has changed hands in the last few days. IF this indicates that the seller is finally done then IPO is going to move back towards the mid140’s very quickly in my view...my fair value is around 170-180p
It’s most likely just punters ‘selling the winners’ to lock-in gains....there’s some panic and a bear market feel to things in various corners of AIM at the moment; selling out performers is classic investor behaviour under duress...
i think selling in Ceres will be bitterly regretted but can’t blame people for trying to grab a profit....
from today's Fiercebiotech.
"After having invested in Morphic Therapeutic’s A and B rounds, AbbVie is pulling the trigger on an R&D deal. The drugmaker is ponying up $100 million for the option to exclusively license multiple programs from Morphic that target fibrotic diseases.
Morphic’s pipeline consists of oral integrin inhibitors—integrin being a cell surface receptor found on most cells. Integrin signaling is involved in many cellular functions and abnormal signaling has been implicated in fibrosis, autoimmune diseases and immuno-oncology.
Under the agreement, Morphic will carry out R&D work on its fibrosis drugs through IND-enabling studies. At that point, AbbVie will be able to decide for each compound whether it will pay a license fee and then pick up responsibility for the global development and commercialization of the drug. Morphic could also bag clinical and commercial milestone payments and royalties for each drug that AbbVie takes forward.
Morphic also retains the option to share development costs with AbbVie on liver fibrosis indications, in exchange for “enhanced royalties.”
“Those liver markets are big,” said Morphic CEO Praveen Tipirneni, M.D. “With NASH, cirrhotic liver and so on ... we obviously had to have something pretty special to negotiate those kinds of rights.”
I’m impressed with the management here. Clearly the trial data was a disappointment. But having the data from the roll-over patients from the Phase 2 trial has been incredibly useful / powerful. This is a chronic treatment. People will be taking these products for a lifetime. There’s not one biotech of any size which has not had a trial setback in its time. I think this will be seen as a minor blip in time. At least holders know the management are doing all they can in a calm, measured way, which is bound to impress the regulators.
Yes. The market maker knew it was good news. He/she collapsed the bid y’day afternoon to try and gather some scraps of stock to facilitate the buys we are now seeing....still, am surprised not to have seen an RNS this morn, not that we necessarily need it...
Agreed....can only be matter of time till we see the formal release on this news.
i also completely agree with Rich. This is such a valuable therapeutic target area that the numbers could really surprise.
Final point: think we haven't see the last of Astra in respiratory...They've had set-backs in the alternative paths they chose over SNG001 a couple of years back. They know the quality of the output from this team..
No cure for our boredom but limited risk of dilution....
any position here is option money as we wait for deal news. My sense is that these guys want to get themselves in good-enough nick to be taken-out.
I still back Barlow as being cleverer and better connected than the average bear. I will give him another six months and see what news he can generate....
you've just got to wait....it's in a no-man's land at the moment. it's owned by clever, long-term-focused concept/innovation investors like Lansdowne and Woodford, but it hasn't yet got the top-line growth or the ebitda growth that the more conventional growth investors need before buying. There's going to be a set of results in the next year, if all keeps on going well, which will allow the conventional guys to buy it and then it will re-rate very sharply (and/or it will be taken-out by someone like Bayer)...I'm waiting for it to go up 3 or 4x before considering my next move.
hey, Davewin, I'd relax on the h1 17 vs h1 18 revenue situation. It's just because of the sequencing of orders. the new generation of polymers, finally formulated earlier this year, are replacing the first generation stuff so legacy orders fade before new orders pick-up.
what's exciting is that the new generation stuff is the real deal in terms of formulation and performance and so it will start to generate a far faster growth rate than the first generation stuff, because it's patently obvious to anybody looking at the performance data that it's as good as the global best-in-class AND it's sustainable. The first generation stuff performed well and was sustainable, etc. but wasn't quite as good in all conditions as it could have been (the standards and testing requirements for dishwasher tablet ingredients are incredibly high in these consumer-facing businesses).
As I understand it, the new generation stuff is why we suddenly have the real, rapid progress with Akzo...Akzo know the new gen product is world-class and know that they can sell (a lot) of it. The Akzo agreement by December is a huge, transformational catalyst for the stock - if it occurs. good luck!
Yes, tiny volumes, tiny free-float. It’s plain ridiculous to be down here given the sound progress and the opportunity in the endocrine space, but it’s not unique. a number of innovation stocks have traded down over the summer. I presume the valuation anomaly will attract buyers at some point but have given up trying to guess when!
We do have first read of phase 3 data in early October so not too long to wait for that and other catalysts before year- end.
Diurnal is a fine company with powerful IP and profound patient impact. Good luck!
just a reminder of how hot the NASH area is and what we're playing for....from today's FierceBiotech:
Viking Therapeutics has proven once again that nothing whips up biotech investors like positive Phase II numbers for NASH.
The biotech’s shares rocketed up more than 100% Tuesday morning on Viking’s boast that VK2809 slashed liver fat content — a biomarker for the disease — while delivering a drop of 20% or more in LDL in the mid-stage study.
Below is a para from a release by Swiss spec chem company, Clariant. It has announced a major restructuring and collaboration (with SABIC). I’ve pasted it because it shows that ITX is in exactly the right place in terms of global chem trends/demand.....we now just need to see the start of momentum in the croda and Akzo product lines....
The Business Area Care Chemicals expects to continue to grow above the market, at a more accelerated pace. This additional step up in growth will result from offering more innovative sustainable solutions which meet the market's increasing demand for convenience, renewable and natural products. The entry into new market segments will also support this above average growth. Consumer Care, which is comprised of Personal Care, Home Care, Crop Solutions as well as Health Care, will be the main driver of this Business Area's expansion strategy. The higher degree of specialties in Care Chemicals and the offering of more highly specified solutions will drive not only growth but also increase profitability to new heights.
you make a good point. in my experience, it's possible for a good corporate broker to find stock from existing investors and limited new issue under dis-application of pre-emption rights (typically new issues under 10% of share cap) for a new II to start to build a position. Everybody benefits from a diversified register and a new II or two can help to cornerstone any further capital raise to accelerate growth. But i'm not suggesting new issue of TRX stock here at 9p!
at least we're now on a path to break-even and that allows TRX to start to screen for other investors to consider.
one of the issues for so many of these woodford and invesco names is the concentration of ownership...it just means the share price carries enhanced gearing to share sales/purchases and sentiment...For the likes of TRX and Xeros, to name just two, that's been a curse as Brexit / UK-focused fund under-performance has driven sentiment down and private investors have run for the hills.
It does mean that when sentiment turns these stocks are going to move a lot higher, very quickly because underlying op performance has been good.